Marvel Biotechnology presents new adenosine A2A receptor antagonists
June 28, 2023
Marvel Biotechnology Inc. has divulged purine compounds acting as adenosine A2A receptor (ADORA2A) antagonists reported to be useful for the treatment of cancer, depression, anxiety disorder, multiple sclerosis, nonalcoholic steatohepatitis, scleroderma, Alzheimer’s disease and Parkinson’s disease.